Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 3, 2022
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation studyMarquita Camilleri, Georgios Bekris, Govundeep Sidhu, et al.
British Journal of Haematology|August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathyRicha Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid LeukemiaOlga Salamero, Pau Montesinos, Christophe Willekens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B TrialRakesh Popat, Bradley Augustson, Paul Cannell, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
British Journal of Cancer|May 22, 2020
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen designDimitrios A Koutoukidis, Joanne Land, Allan Hackshaw, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 2, 2024
The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation studyCaroline Buck, Francisco Brenes Castillo, Elena Bettio, et al.
Clinical Hematology International|October 1, 2021
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in MyelomaTreen Carson Michael Morris, Mary B Drake, Paul J Kettle, et al.
British Journal of Haematology|January 28, 2020
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosisOliver C Cohen, Faye Sharpley, Julian D Gillmore, et al.
The Lancet. Haematology|June 30, 2025
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 studyShaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Pageof 9